Nutromics

About Nutromics

Nutromics, an Australian-born MedTech company established in 2017 by co-founders Peter Vranes and Hitesh Mehta, is advancing the field of preventative healthcare through its continuous molecular monitoring (CMM) platform. The company's vision is to eliminate preventable deaths by providing real-time diagnostic data. Vranes, with a background in engineering and finance, and Mehta, a biomedical engineer, combined their expertise to address the critical gap between intermittent testing and the need for continuous physiological insights. Their journey was fueled by the realization that periodic blood tests often fail to capture the dynamic nature of the human body, leading to delayed or missed diagnoses for critical conditions.

The core of Nutromics' offering is a wearable patch equipped with DNA-based sensors on microneedle tips. This device is designed to be worn on the skin, where it can painlessly access interstitial fluid to provide continuous and real-time data on multiple molecular targets. This approach marks a significant departure from traditional, episodic blood draws, enabling clinicians to observe trends and make timely interventions. The initial focus for this technology is on therapeutic drug monitoring (TDM), particularly for managing the antibiotic vancomycin, which has a narrow therapeutic window and is crucial for treating life-threatening infections. The platform's capability to provide immediate data aims to optimize drug dosage, thereby reducing the risks of toxicity and antibiotic resistance.

Operating within the burgeoning MedTech and diagnostics market, Nutromics targets healthcare providers, including hospitals and clinics, as its primary clientele. The business model is centered on providing this diagnostic-as-a-service platform, which will likely involve the sale of the wearable patches and a subscription or-per-use model for the accompanying data analysis software. The company has secured substantial financial backing, raising US$20 million through a combination of a US$14 million Series A funding round and a US$6 million grant from the Australian government's Medical Research Future Fund (MRFF). This capital is being deployed to fund clinical trials, expand the research and development team, and scale up manufacturing capabilities. Notable investors include Dexcom Ventures, VU Venture Partners, and Artesian Ventures. With teams located in both Australia and the United States, Nutromics is strategically positioned to navigate the regulatory landscapes and market demands of these key regions as it works towards commercializing its pioneering diagnostic solution.